



FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG

August 28, 2017

**BUSINESS EXCELLENCE AWARD NAMES CARDIOCOMM SOLUTIONS AS THE
MEDICAL SOFTWARE DEVELOPMENT FIRM OF 2017**

Consumer wearable tech and M-Health markets to benefit from credible medical software innovations

TORONTO, ONTARIO - Established medical electrocardiogram ("ECG") software and device manufacturer CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"), today announced it has been awarded the 2017 Innovation and Excellence Award for Best in Medical Software Development. The award is sponsored by the International Business Innovation Association and is managed by UK-based Corporate LiveWire.

CardioComm Solutions was awarded the 2017 award for Best In Medical Software Development based on their efforts to broaden access to a growing range of easy to use consumer medical-wellness products. Drawing from CardioComm Solutions' well developed hospital ECG connectivity and management technologies, they are now offering a medical software "back office" to their partners and customers that is device and biosign agnostic and that will provide credibility and certainty in the results generated and a continuity of medical excellence. The award recognizes CardioComm Solutions' credibility as a trusted provider of medical software as well as their efforts to help transform their industry, set industry trends and standards of excellence and for the significant advances already made in terms of innovation and improvement.

CardioComm Solutions was the first company to receive Canadian and US regulatory approvals for the over the counter ("OTC") sale of a consumer device allowing any person to take their own ECG anywhere. CardioComm Solutions continues to be recognized as the leading trusted provider of medical software solutions. Since the release of the HeartCheck™ ECG PEN, CardioComm Solutions has focused on leveraging their expertise as a provider of device communication, connectivity and data management solutions that enable easier market access for novel and disruptive hardware health monitoring technologies. The Company has been solidifying strategic alliances and distribution agreements with device manufacturers and tele-health providers globally with plans for the release of ECG and other biosign monitoring solutions. These solutions will be utilizing devices that are easier to use and will allow access to wearable, sports, medical and handheld device/heart monitoring markets globally. Some of the devices will carry CardioComm Solutions' HeartCheck™ brand, while others will be driven by CardioComm Solutions' back end software. These include a battery-less NFC (near field communication) connected handheld ECG Card and Smartphone connected devices such as a waterproof sports band that would compete in the Fitbit markets. Most recently CardioComm Solutions is testing a one and multi-lead ECG lead Sports Patch that can be worn by active consumers and patients discreetly under their clothing. Leveraging access to multiple biosign monitoring devices and telehealth solutions in both consumer and medical markets will provide CardioComm Solutions wider and less restricted market access as compared to its competitors.

In selecting their winners, Corporate Live Wire reviewed information gathered by a research team that utilized recommendations from over 100,000 professionals to nominate associations, companies and individuals based on their achievements and strengths. CardioComm Solutions is now listed in a published guide that is distributed to over 500,000 businesses and professionals and is available to the Corporate LiveWire website which is visited by approximately 50,000 readers monthly and within an e-newsletter provided to over 30,000 registered subscribers. The readership community is comprised of CEOs, CFOs, MDs and Directors of national and multi-national companies from the business community and bankers, brokers, consultants, lawyers and accountants from the corporate finance advisory community.

CardioComm Solutions will be providing further updates respecting their medical and consumer ECG recording technologies and award updates. CardioComm Solutions has earned the ISO 13485 certification, is HPB approved, HIPAA compliant and holds clearances for the sale of the HeartCheck™ technologies from the European Union (CE Mark), the USA (FDA), China (CFDA) and Canada (Health Canada). To learn more about the CardioComm Solutions' products, please see the Company's websites www.theheartcheck.com and www.cardiocomm.com.

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.



FOR FURTHER INFORMATION PLEASE CONTACT:

Etienne Grima, Chief Executive Officer

1-877-977-9425 x 227

investorrelations@cardiocommsolutions.com

www.cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (*Continuous Disclosure Obligations*).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.